Skip to main
IMUX

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunic is well-positioned for future success due to their recent financing which allows for de-risking of late-stage development and potential commercial infrastructure. The company's differentiated mechanism of action targeting both inflammatory relapse activity and neuroprotection has shown positive results in clinical trials, and the upcoming Phase 3 trials and potential launch could solidify their position in the market. The lack of current treatments addressing PIRA and overall disability accumulation could make vidofludimus calcium a valuable option for patients, further supporting Immunic's potential for growth.

Bears say

Immunic is facing several challenges as a clinical-stage biopharmaceutical company, including weakened investor demand as evidenced by the recent downgrade to Hold and upcoming reverse stock split. Additionally, the company's future commercial viability may be hindered by its dependence on the success of its Phase 3 trials in multiple sclerosis and the dilution of its shares through future capital raises. While the recent financing and leadership changes may strengthen the company's position, these fundamental concerns suggest a negative outlook on Immunic's stock.

Immunic Inc (IMUX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Immunic Inc (IMUX) has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.